the Efficacy and Safety of Dalpiciclib Combined With Third-generation EGFR-TKI in Patients With EGFR Mutation and Meningial Metastasis in Non-small Cell Lung Cancer Progressing Through Third-generation TKI and Platinum-containing Two-drug Chemotherapy

Clinical trial NCT05497076 · UNKNOWN

Trial details

NCT number: NCT05497076
Sponsor: Fujian Cancer Hospital
Status: UNKNOWN
Study type: OBSERVATIONAL

Non-small Cell Lung Cancer Confirmed by Histopathology or Cytology The TNM (8th) Phase is IV With EGFR Mutations Meningeal Progression Occurred After Previous Platinum-containing Two-drug Chemotherapy and Third-generation EGFR-TKI Treatment Male or Female The Age of 18 Years Old or More ECOG PS 0 to 2 Points

Start date: 2022-09-01
Primary completion: 2024-01-01
Enrollment: 9

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.